US 8846713
Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors
granted A61KA61K31/4353A61K31/4355
Quick answer
US patent 8846713 (Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors) held by Takeda Pharmaceutical Company Limited expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Sep 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 2
- CPC classes
- A61K, A61K31/4353, A61K31/4355, A61K31/437, A61K31/4427